Ashleyk writes "While we wait, forever, for clinical trials to succeed, maybe Curcumin at about 2 grams a day could clear out a-Synclein in PD and Alzheimer's".

The situation with curcumin is part of the same old problem: a substance that may be a useful therapy, that is probably safe, with some data in its favour, but not enough human, clinical trial data to be definitive. It may be that whether it works will never be known because it offers insufficient profits for anyone to do a proper clinical trial.

There are dangers in taking a substance that is not properly tested. But there are also dangers, the lost benefit, the relentless progression of PD, in not taking a substance that may be efficacious. The issue is to get the balance right.

The way forward, as I see it, is to get Parkinson's experts to say, based on their theoretical knowledge, animal test results and limited human data, what unproven therapies they would take if they had PD. PwP would choose whether to take the promising therapies, taking into account their relative risks. Their response to the new potential therapies would be monitored.

The fastest response should come from Parkinson's experts who have PD. It would be useful to know what non-approved therapies they take. If they are prepared to be open about this, we could have many new potential therapies to consider within a month.

John